Your browser doesn't support javascript.
loading
PROTAC-DB 2.0: an updated database of PROTACs.
Weng, Gaoqi; Cai, Xuanyan; Cao, Dongsheng; Du, Hongyan; Shen, Chao; Deng, Yafeng; He, Qiaojun; Yang, Bo; Li, Dan; Hou, Tingjun.
Afiliação
  • Weng G; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • Cai X; CarbonSilicon AI Technology Co., Ltd, Hangzhou 310018, Zhejiang, China.
  • Cao D; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • Du H; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • Shen C; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410004, Hunan, China.
  • Deng Y; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • He Q; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • Yang B; CarbonSilicon AI Technology Co., Ltd, Hangzhou 310018, Zhejiang, China.
  • Li D; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • Hou T; Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
Nucleic Acids Res ; 51(D1): D1367-D1372, 2023 01 06.
Article em En | MEDLINE | ID: mdl-36300631
ABSTRACT
Proteolysis targeting chimeras (PROTACs), which harness the ubiquitin-proteasome system to selectively induce targeted protein degradation, represent an emerging therapeutic technology with the potential to modulate traditional undruggable targets. Over the past few years, this technology has moved from academia to industry and more than 10 PROTACs have been advanced into clinical trials. However, designing potent PROTACs with desirable drug-like properties still remains a great challenge. Here, we report an updated online database, PROTAC-DB 2.0, which is a repository of structural and experimental data about PROTACs. In this 2nd release, we expanded the number of PROTACs to 3270, which corresponds to a 96% expansion over the first version. Meanwhile, the numbers of warheads (small molecules targeting the proteins of interest), linkers, and E3 ligands (small molecules recruiting E3 ligases) have increased to over 360, 1500 and 80, respectively. In addition, given the importance and the limited number of the crystal target-PROTAC-E3 ternary complex structures, we provide the predicted ternary complex structures for PROTACs with good degradation capability using our PROTAC-Model method. To further facilitate the analysis of PROTAC data, a new filtering strategy based on the E3 ligases is also added. PROTAC-DB 2.0 is available online at http//cadd.zju.edu.cn/protacdb/.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bases de Dados de Proteínas / Complexo de Endopeptidases do Proteassoma / Proteólise Tipo de estudo: Prognostic_studies Idioma: En Revista: Nucleic Acids Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bases de Dados de Proteínas / Complexo de Endopeptidases do Proteassoma / Proteólise Tipo de estudo: Prognostic_studies Idioma: En Revista: Nucleic Acids Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China